Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.

Scientific reports - 11 Dec 2015

Lindhurst Marjorie J, Yourick Miranda R, Yu Yi, Savage Ronald E, Ferrari Dora, Biesecker Leslie G

Abstract excerpt

A somatic activating mutation in AKT1, c.49G>A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome. ARQ 092 is an allosteric pan-AKT inhibitor under development for treatment in cancer. We tested the efficacy of this drug for suppressing AKT signaling in cells and tissues from patients with Proteus syndrome. ARQ 092...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Becaplermin
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Phosphorylation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins c-sis

Source

Open in PubMed Open full text

Identifiers

PMID: 26657992
DOI: 10.1038/srep17162
PMCID: PMC4675973

Genes

AKT1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.PMID 26657992Read ↗

Perturbations of the AKT signaling pathway in human cancer.Semantic proximity Read ↗

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).Semantic proximity Read ↗

The Akt pathway in oncology therapy and beyond (Review)Semantic proximity Read ↗

Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.Semantic proximity Read ↗

AKT Inhibition in Solid Tumors With AKT1 Mutations.Semantic proximity Read ↗

A mosaic activating mutation in AKT1 associated with the Proteus syndrome.Semantic proximity Read ↗

AKT isoform-specific expression and activation across cancer lineages.Semantic proximity Read ↗

Inhibitors in AKTion: ATP-competitive vs allosteric.Semantic proximity Read ↗

A Mosaic Activating Mutation in AKT1 Associated with the Proteus SyndromeSemantic proximity Read ↗

Development of a new model system to dissect isoform specific Akt signalling in adipocytes.Semantic proximity Read ↗

BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.Semantic proximity Read ↗

Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.